NASDAQ:XON - Intrexon Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intrexon Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.65 -0.29 (-4.88 %) (As of 01/24/2020 03:31 PM ET) Add Compare Today's Range$5.63Now: $5.65▼$5.9750-Day Range$5.37MA: $5.95▼$7.1952-Week Range$3.95Now: $5.65▼$8.77Volume38,581 shsAverage Volume1.36 million shsMarket Capitalization$919.14 millionP/E RatioN/ADividend YieldN/ABeta2.26 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XON Previous Symbol CUSIPN/A CIK1356090 Webhttp://www.dna.com/ Phone301-556-9900Debt Debt-to-Equity Ratio0.97 Current Ratio1.92 Quick Ratio1.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$160.57 million Price / Sales5.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book2.05Profitability EPS (Most Recent Fiscal Year)($1.37) Net Income$-509,340,000.00 Net Margins-393.13% Return on Equity-45.51% Return on Assets-20.69%Miscellaneous EmployeesN/A Outstanding Shares162,680,000Market Cap$919.14 million Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive XON News and Ratings via Email Sign-up to receive the latest news and ratings for XON and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:XON Rates by TradingView Intrexon (NASDAQ:XON) Frequently Asked Questions What is Intrexon's stock symbol? Intrexon trades on the NASDAQ under the ticker symbol "XON." How were Intrexon's earnings last quarter? Intrexon Corp (NASDAQ:XON) issued its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.02. The biotechnology company had revenue of $23.04 million for the quarter, compared to analyst estimates of $32.16 million. Intrexon had a negative return on equity of 45.51% and a negative net margin of 393.13%. View Intrexon's Earnings History. When is Intrexon's next earnings date? Intrexon is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Intrexon. What price target have analysts set for XON? 3 analysts have issued 12 month price targets for Intrexon's stock. Their forecasts range from $6.00 to $43.00. On average, they expect Intrexon's share price to reach $19.67 in the next twelve months. This suggests a possible upside of 248.7% from the stock's current price. View Analyst Price Targets for Intrexon. What is the consensus analysts' recommendation for Intrexon? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intrexon in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intrexon. What are Wall Street analysts saying about Intrexon stock? Here are some recent quotes from research analysts about Intrexon stock: 1. Northland Securities analysts commented, "We believe the company will spin-off its assets as the company has backed away from its target cash burn goal of $70M." (8/12/2019) 2. According to Zacks Investment Research, "We are positive on Intrexon’s efforts to expand through acquisitions, exclusive channel collaborations and joint ventures. Intrexon's expanding portfolio of technologies has enabled it to develop a robust pipeline of candidates in partnership deals, targeting a broad range of diseases including cancer. Additionally, the company announced the formation of a wholly-owned subsidiary, Precigen, Inc. as part of its structural alternatives, so that it can take better decisions regarding its health business. However, the company largely depends on ECCs and license, and collaboration deals for revenues. Any unfavorable outcome from the development of these might be a major setback and hurt the company’s prospects too. Though, estimates have remained stable ahead of its Q4 earnings release, Intrexon has a positive record of earnings surprises in recent quarters." (1/26/2019) Has Intrexon been receiving favorable news coverage? News coverage about XON stock has been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intrexon earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Intrexon. Who are some of Intrexon's key competitors? Some companies that are related to Intrexon include Medpace (MEDP), National Research (NRC), Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Anavex Life Sciences (AVXL), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX) and Vitality Biopharma (VBIO). What other stocks do shareholders of Intrexon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intrexon investors own include Nordic American Tanker (NAT), ZIOPHARM Oncology (ZIOP), Hess (HES), Boeing (BA), Opko Health (OPK), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Alibaba Group (BABA) and General Electric (GE). Who are Intrexon's key executives? Intrexon's management team includes the folowing people: Mr. Randal J. Kirk, Chairman & CEO (Age 65)Mr. Rick L. Sterling, Chief Financial Officer (Age 54)Mr. Donald P. Lehr, Chief Legal Officer & Corp. Sec. (Age 43)Mr. Robert F. Walsh III, Sr. VP of Energy & Fine Chemicals Platforms (Age 60)Mr. Jeffrey Thomas Perez, Sr. VP of Intellectual Property Affairs (Age 46) Who are Intrexon's major shareholders? Intrexon's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (0.14%), Alpine Global Management LLC (0.05%), Janney Montgomery Scott LLC (0.03%) and Addison Capital Co (0.01%). Company insiders that own Intrexon stock include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Institutional Ownership Trends for Intrexon. Which major investors are selling Intrexon stock? XON stock was sold by a variety of institutional investors in the last quarter, including Addison Capital Co and Janney Montgomery Scott LLC. Company insiders that have sold Intrexon company stock in the last year include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Insider Buying and Selling for Intrexon. Which major investors are buying Intrexon stock? XON stock was acquired by a variety of institutional investors in the last quarter, including Alpine Global Management LLC and Sanders Morris Harris LLC. View Insider Buying and Selling for Intrexon. How do I buy shares of Intrexon? Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Intrexon's stock price today? One share of XON stock can currently be purchased for approximately $5.64. How big of a company is Intrexon? Intrexon has a market capitalization of $917.52 million and generates $160.57 million in revenue each year. The biotechnology company earns $-509,340,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. View Additional Information About Intrexon. What is Intrexon's official website? The official website for Intrexon is http://www.dna.com/. How can I contact Intrexon? Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected] MarketBeat Community Rating for Intrexon (NASDAQ XON)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 380 (Vote Outperform)Underperform Votes: 356 (Vote Underperform)Total Votes: 736MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe XON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XON will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: Diluted Earnings Per Share
